Hi ECT rep,
First of all thanks for your time.
I note your comments on future revenues being speculative, that is clearly understood by most shareholders.
Is ECT working with Arrowhead (ABID) to update the Due Diligence and Valuation Report following the signed MPA plus sub agreements? Last report dating 11 July 2017 had a fair value bracket of 0.034 to 0.042 per share.
I think albeit deemed as speculative it would be informative for current and future shareholders to have Arrowhead asses what value has been added through the commercial arrangements or alternatively to what extend the project has been de-risked.
Cheers
ECT_Rep taking questions, page-41
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ECT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $11.10M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $1.515K | 504.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 13357839 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 11826592 | 27 |
View Market Depth
| Last trade - 15.57pm 28/06/2024 (20 minute delay) ? |
| ECT (ASX) Chart |